These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 25851995

  • 1. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A, Menzel S, Gupta R, Al-Sharida S, Farag A, Haider M, Akbulut N, Mustafa N, Thein SL.
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract] [Full Text] [Related]

  • 2. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Jul; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 3. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 4. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P, Barretto de Mello A, Figueiredo MS.
    Am J Hematol; 2005 Mar 28; 78(3):243-4. PubMed ID: 15726590
    [Abstract] [Full Text] [Related]

  • 5. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 28; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 6. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP.
    Pharmacogenomics; 2012 Oct 28; 13(13):1487-500. PubMed ID: 23057549
    [Abstract] [Full Text] [Related]

  • 7. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM, Wakamb GK, Mulangu AM, Nkashama GM, Kupa BK, Numbi OL.
    Pan Afr Med J; 2015 Oct 28; 21():124. PubMed ID: 26327961
    [Abstract] [Full Text] [Related]

  • 8. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE, BABY HUG Investigators.
    Am J Hematol; 2013 Jul 28; 88(7):571-6. PubMed ID: 23606168
    [Abstract] [Full Text] [Related]

  • 9. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996 Jul 28; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 10. Sickle cell paths converge on hydroxyurea.
    Platt OS.
    Nat Med; 1995 Apr 28; 1(4):307-8. PubMed ID: 7585059
    [No Abstract] [Full Text] [Related]

  • 11. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
    Gravia A, Chondrou V, Sgourou A, Papantoni I, Borg J, Katsila T, Papachatzopoulou A, Patrinos GP.
    Pharmacogenomics; 2014 Jul 28; 15(10):1355-64. PubMed ID: 25155936
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM, Taher AT, Cappellini MD, Sankaran VG.
    Blood; 2013 Mar 21; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [Abstract] [Full Text] [Related]

  • 13. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A, Rigano P, Troia A, Calzolari R, Scazzone C, Maggio A, Steinberg MH, Di Marzo R.
    Eur J Haematol; 2014 Jan 21; 92(1):66-72. PubMed ID: 24112139
    [Abstract] [Full Text] [Related]

  • 14. The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.
    Adekile A.
    Med Princ Pract; 2021 Jan 21; 30(3):201-211. PubMed ID: 32892201
    [Abstract] [Full Text] [Related]

  • 15. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
    Green NS, Barral S.
    Pediatr Blood Cancer; 2011 Feb 21; 56(2):177-81. PubMed ID: 20830771
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia.
    Sales RR, Nogueira BL, Luizon MR.
    Pharmacogenomics; 2022 May 21; 23(7):393-396. PubMed ID: 35546339
    [No Abstract] [Full Text] [Related]

  • 17. The role of hydroxyurea in sickle cell disease.
    Halsey C, Roberts IA.
    Br J Haematol; 2003 Jan 21; 120(2):177-86. PubMed ID: 12542474
    [No Abstract] [Full Text] [Related]

  • 18. Seeking a way to alleviate sickle cell disease.
    Mitka M.
    JAMA; 2003 Jan 21; 288(16):1970. PubMed ID: 12387636
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.